Basic Information
| LncRNA/CircRNA Name | LINC01134 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RIP etc |
| Sample | HCC tissues and para-tumor tissues,cell lines(QSG-7701, SNU-449, HepG2, HLF, Huh-7) |
| Expression Pattern | differential expressed |
| Function Description | Knockdown of linc01134 inhibited proliferation, migration and epithelial-mesenchymal transition (EMT), yet promoting apoptosis in HCC cells. Mechanically, linc01134 acted as miR-324-5p sponge and interacted with insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) to increase the stability of YY1 mRNA expression. |
| Pubmed ID | 32272940 |
| Year | 2020 |
| Title | Molecular Interplay Between linc01134 and YY1 Dictates Hepatocellular Carcinoma Progression |
External Links
| Links for LINC01134 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |